Key result
Novel gene therapies and stent-based drug delivery show promise against in-stent restenosis.
Why the study?
In-stent restenosis is an increasingly frequent and histologically distinct pathobiologic process with limited pharmacologic and mechanical treatment options until recent advances.
Answers are grounded in this paper and cite their sources.
This review highlights that while in-stent restenosis has been a growing challenge, emerging technologies like drug-eluting stents and gene therapies offer significant potential to reduce its incidence.
In-stent restenosis (ISR) is a novel pathobiologic process, histologically distinct from restenosis after balloon angioplasty and comprised largely of neointima formation. As percutaneous coronary intervention increasingly involves the use of stents, ISR is also becoming correspondingly more frequent. In this review, we examine the available studies of the histology and pathogenesis of ISR, with particular reference to porcine and other animal models. An overview of mechanical treatments is then provided, which includes PTCA, directional coronary atherectomy and high speed rotational atherectomy. Radiation-based therapies are discussed, including a summary of current problems associated with this modality of treatment. Finally, novel strategies for the prevention of ISR are addressed, including novel developments in stents and stent coatings, conventional drugs, nucleic acid-based drugs and gene transfer. Until recently, limited pharmacologic and mechanical treatment options have been available for both treatment and prevention of ISR. However, recent advances in gene modification and gene transfer therapies and, more particularly, in local stent-based drug delivery systems make it conceivable that the incidence of ISR will now be seriously challenged.
No takes yet. Share an insight, caveat, or question.
Lowe et al. (2002) conducted a review in Coronary in-stent restenosis. Treatments and prevention strategies for in-stent restenosis was evaluated. Recent advances in gene modification, gene transfer therapies, and local stent-based drug delivery systems offer promising new strategies for the prevention and treatment of in-stent restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: